<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03403426</url>
  </required_header>
  <id_info>
    <org_study_id>RFM-CTO-13001</org_study_id>
    <nct_id>NCT03403426</nct_id>
  </id_info>
  <brief_title>ReFlow Medical Wingman Catheter Wing-IT Clinical Trial</brief_title>
  <acronym>Wing-It</acronym>
  <official_title>A Non-Randomized Study Evaluating the Use of the ReFlow Medical Wingman Catheter to Cross Chronic Total Occlusions in Infrainguinal Peripheral ArTeries</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>ReFlow Medical, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>ReFlow Medical, Inc.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the safety and effectiveness of the ReFlow Medical Wingman Catheter used to cross&#xD;
      de novo or restenotic infrainguinal CTOs that cannot be crossed with a standard guidewire.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Prospective, multi-center, non-randomized single-arm study of the Wingman Catheter to cross a&#xD;
      single infrainguinal peripheral chronic total occlusion (CTO). Safety and effectiveness will&#xD;
      be evaluated during the index procedure through 30-day follow-up.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 13, 2018</start_date>
  <completion_date type="Actual">August 8, 2019</completion_date>
  <primary_completion_date type="Actual">August 8, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Lesions With Successful CTO Crossing Assessed by Angiography</measure>
    <time_frame>Intraprocedural</time_frame>
    <description>While using the Wingman device, successful CTO crossing is identified by successful guidewire placement in the distal true lumen confirmed by angiography with no clinically significant perforations. Assessment by angiography with results reviewed by an independent core lab.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Major Adverse Event (MAE) Rate</measure>
    <time_frame>Assessed from the time of the procedure through 30 days</time_frame>
    <description>Occurrence of significant in-hospital or 30-day MAEs.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Rate of Clinically Significant Perforations</measure>
    <time_frame>Will be assessed from the time of the procedure through 30 days</time_frame>
    <description>Occurrence of clinically significant perforation, after Wingman CTO crossing and PTA of lesion, confirmed by angiography, evaluated by angiographic core lab</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Lesion Success</measure>
    <time_frame>Intraprocedural</time_frame>
    <description>Lesion success, defined as attainment of &lt;50% final residual stenosis of the target lesion using any percutaneous method</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Procedure Success Rate</measure>
    <time_frame>Approximately 24 hours post procedure</time_frame>
    <description>Procedure success, defined as device success and the absence of in-hospital MAEs, clinically significant perforation, clinically significant embolization or Grade C or greater dissection not resolved by visual estimate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of In-hospital AE or MAE</measure>
    <time_frame>Intraprocedural</time_frame>
    <description>Procedure safety defined as any in-hospital AE or MAE following use of a therapeutic interventional device</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total Procedural Time</measure>
    <time_frame>Approximately 24 hours post procedure</time_frame>
    <description>Evaluation of total procedural time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Device Procedural Time</measure>
    <time_frame>Approximately 24 hours post procedure</time_frame>
    <description>Evaluation of procedure time associated with use of the investigational device.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Contrast Use</measure>
    <time_frame>Approximately 24 hours post procedure</time_frame>
    <description>Evaluation of total procedural contrast volume use</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fluoroscopic Time</measure>
    <time_frame>Approximately 24 hours post procedure</time_frame>
    <description>Evaluation of total procedural fluoroscopic time</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">85</enrollment>
  <condition>Chronic Total Occlusion of Artery of the Extremities</condition>
  <arm_group>
    <arm_group_label>Wingman Crossing Catheter</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Use of the device to support CTO crossing</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Wingman Crossing Catheter</intervention_name>
    <description>Endovascular CTO crossing</description>
    <arm_group_label>Wingman Crossing Catheter</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patient is willing and able to provide informed consent.&#xD;
&#xD;
          -  Patient is willing and able to comply with the study protocol.&#xD;
&#xD;
          -  Patient is &gt; 18 years old.&#xD;
&#xD;
          -  Patient has peripheral arterial disease requiring revascularization as evidenced by&#xD;
             contrast, CT or MR angiography.&#xD;
&#xD;
          -  Patient has at least one but not more than two occluded infrainguinal arteries that&#xD;
             are 99-100% stenosed and no flow is observed in the distal lesion except the flow from&#xD;
             collateral circulation.&#xD;
&#xD;
          -  Target lesion(s) is ≥ 1 cm and &lt; 30 cm in length by visual estimate.&#xD;
&#xD;
          -  Target vessel is ≥ 2.0 mm in diameter.&#xD;
&#xD;
          -  Patient has Rutherford Classification of 2-5.&#xD;
&#xD;
          -  Lesion cannot be crossed by concurrent conventional guidewire.&#xD;
&#xD;
          -  Reconstitution of vessel at least 2cm above bifurcation/trifurcation.&#xD;
&#xD;
          -  Occlusion can be within previously implanted stent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patient has a known sensitivity or allergy to contrast materials that cannot be&#xD;
             adequately pre-treated.&#xD;
&#xD;
          -  Patient has a known sensitivity or allergy to all anti-platelet medications.&#xD;
&#xD;
          -  Patient is pregnant or lactating.&#xD;
&#xD;
          -  Patient has a co-existing disease or medical condition contraindicating percutaneous&#xD;
             intervention.&#xD;
&#xD;
          -  Target lesion is in a bypass graft.&#xD;
&#xD;
          -  Patient has had a failed crossing attempt without an intervening intervention on the&#xD;
             target limb within the past 14 days.&#xD;
&#xD;
          -  Patient has a planned surgical or interventional procedure within 30 days after the&#xD;
             study procedure.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>John Laird, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Adventist St. Helena Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Adventist St. Helena Hospital</name>
      <address>
        <city>Saint Helena</city>
        <state>California</state>
        <zip>94574</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>November 29, 2017</study_first_submitted>
  <study_first_submitted_qc>January 17, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">January 18, 2018</study_first_posted>
  <results_first_submitted>October 3, 2020</results_first_submitted>
  <results_first_submitted_qc>January 4, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">January 7, 2021</results_first_posted>
  <last_update_submitted>January 4, 2021</last_update_submitted>
  <last_update_submitted_qc>January 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 7, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <provided_document_section>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>May 20, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/26/NCT03403426/SAP_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>October 3, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/26/NCT03403426/Prot_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Wingman Crossing Catheter</title>
          <description>Use of the device to support CTO crossing&#xD;
Wingman Crossing Catheter: Endovascular CTO crossing</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="85"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="82"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Wingman Crossing Catheter</title>
          <description>Use of the device to support CTO crossing&#xD;
Wingman Crossing Catheter: Endovascular CTO crossing</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="85"/>
          </count_list>
        </analyzed>
        <analyzed>
          <units>lesions</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="86"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <units_analyzed>Participants</units_analyzed>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="71.4" spread="9.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <units_analyzed>Participants</units_analyzed>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="29"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <units_analyzed>Participants</units_analyzed>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="84"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <units_analyzed>Participants</units_analyzed>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="78"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <units_analyzed>Participants</units_analyzed>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Austria</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Germany</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Lesions With Successful CTO Crossing Assessed by Angiography</title>
        <description>While using the Wingman device, successful CTO crossing is identified by successful guidewire placement in the distal true lumen confirmed by angiography with no clinically significant perforations. Assessment by angiography with results reviewed by an independent core lab.</description>
        <time_frame>Intraprocedural</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Wingman Crossing Catheter</title>
            <description>Use of the device to support CTO crossing&#xD;
Wingman Crossing Catheter: Endovascular CTO crossing</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Lesions With Successful CTO Crossing Assessed by Angiography</title>
          <description>While using the Wingman device, successful CTO crossing is identified by successful guidewire placement in the distal true lumen confirmed by angiography with no clinically significant perforations. Assessment by angiography with results reviewed by an independent core lab.</description>
          <units>lesions</units>
          <param>Count of Units</param>
          <units_analyzed>lesions</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="85"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>lesions</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="86"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Major Adverse Event (MAE) Rate</title>
        <description>Occurrence of significant in-hospital or 30-day MAEs.</description>
        <time_frame>Assessed from the time of the procedure through 30 days</time_frame>
        <population>Denominator is not to equal to 85 due to incomplete 30-day follow-up data. 1 subject was lost to follow-up and 1 subject withdrew after 30 days but did not have a 30 day visit.&#xD;
All 85 patients were monitored for AEs in-hospital, but as the primary endpoint is through 30 days 2 of the patients were not included in the analysis after they withdrew or were lost to follow-up. Any adverse events were captured and reported in the adverse event module for all 85 patients.</population>
        <group_list>
          <group group_id="O1">
            <title>Wingman Crossing Catheter</title>
            <description>Use of the device to support CTO crossing&#xD;
Wingman Crossing Catheter: Endovascular CTO crossing</description>
          </group>
        </group_list>
        <measure>
          <title>Major Adverse Event (MAE) Rate</title>
          <description>Occurrence of significant in-hospital or 30-day MAEs.</description>
          <population>Denominator is not to equal to 85 due to incomplete 30-day follow-up data. 1 subject was lost to follow-up and 1 subject withdrew after 30 days but did not have a 30 day visit.&#xD;
All 85 patients were monitored for AEs in-hospital, but as the primary endpoint is through 30 days 2 of the patients were not included in the analysis after they withdrew or were lost to follow-up. Any adverse events were captured and reported in the adverse event module for all 85 patients.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="83"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Rate of Clinically Significant Perforations</title>
        <description>Occurrence of clinically significant perforation, after Wingman CTO crossing and PTA of lesion, confirmed by angiography, evaluated by angiographic core lab</description>
        <time_frame>Will be assessed from the time of the procedure through 30 days</time_frame>
        <population>Denominator is not to equal to 85 due to incomplete 30-day follow-up data. 1 subject was lost to follow-up and 1 subject withdrew after 30 days but did not have a 30 day visit.</population>
        <group_list>
          <group group_id="O1">
            <title>Wingman Crossing Catheter</title>
            <description>Use of the device to support CTO crossing&#xD;
Wingman Crossing Catheter: Endovascular CTO crossing</description>
          </group>
        </group_list>
        <measure>
          <title>Rate of Clinically Significant Perforations</title>
          <description>Occurrence of clinically significant perforation, after Wingman CTO crossing and PTA of lesion, confirmed by angiography, evaluated by angiographic core lab</description>
          <population>Denominator is not to equal to 85 due to incomplete 30-day follow-up data. 1 subject was lost to follow-up and 1 subject withdrew after 30 days but did not have a 30 day visit.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="83"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Lesion Success</title>
        <description>Lesion success, defined as attainment of &lt;50% final residual stenosis of the target lesion using any percutaneous method</description>
        <time_frame>Intraprocedural</time_frame>
        <population>Denominator is not equal to 86 lesion due to missing data points in 3 patients.</population>
        <group_list>
          <group group_id="O1">
            <title>Wingman Crossing Catheter</title>
            <description>Use of the device to support CTO crossing&#xD;
Wingman Crossing Catheter: Endovascular CTO crossing</description>
          </group>
        </group_list>
        <measure>
          <title>Lesion Success</title>
          <description>Lesion success, defined as attainment of &lt;50% final residual stenosis of the target lesion using any percutaneous method</description>
          <population>Denominator is not equal to 86 lesion due to missing data points in 3 patients.</population>
          <units>Lesions</units>
          <param>Count of Units</param>
          <units_analyzed>Lesions</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="85"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Lesions</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="83"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Procedure Success Rate</title>
        <description>Procedure success, defined as device success and the absence of in-hospital MAEs, clinically significant perforation, clinically significant embolization or Grade C or greater dissection not resolved by visual estimate</description>
        <time_frame>Approximately 24 hours post procedure</time_frame>
        <population>Denominator is not to equal to 85 due to missing data points on 3 subjects.</population>
        <group_list>
          <group group_id="O1">
            <title>Wingman Crossing Catheter</title>
            <description>Use of the device to support CTO crossing&#xD;
Wingman Crossing Catheter: Endovascular CTO crossing</description>
          </group>
        </group_list>
        <measure>
          <title>Procedure Success Rate</title>
          <description>Procedure success, defined as device success and the absence of in-hospital MAEs, clinically significant perforation, clinically significant embolization or Grade C or greater dissection not resolved by visual estimate</description>
          <population>Denominator is not to equal to 85 due to missing data points on 3 subjects.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="82"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Incidence of In-hospital AE or MAE</title>
        <description>Procedure safety defined as any in-hospital AE or MAE following use of a therapeutic interventional device</description>
        <time_frame>Intraprocedural</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Wingman Crossing Catheter</title>
            <description>Use of the device to support CTO crossing&#xD;
Wingman Crossing Catheter: Endovascular CTO crossing</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of In-hospital AE or MAE</title>
          <description>Procedure safety defined as any in-hospital AE or MAE following use of a therapeutic interventional device</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="85"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Total Procedural Time</title>
        <description>Evaluation of total procedural time</description>
        <time_frame>Approximately 24 hours post procedure</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Wingman Crossing Catheter</title>
            <description>Use of the device to support CTO crossing&#xD;
Wingman Crossing Catheter: Endovascular CTO crossing</description>
          </group>
        </group_list>
        <measure>
          <title>Total Procedural Time</title>
          <description>Evaluation of total procedural time</description>
          <units>minutes</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="85"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="102" spread="48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Device Procedural Time</title>
        <description>Evaluation of procedure time associated with use of the investigational device.</description>
        <time_frame>Approximately 24 hours post procedure</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Wingman Crossing Catheter</title>
            <description>Use of the device to support CTO crossing&#xD;
Wingman Crossing Catheter: Endovascular CTO crossing</description>
          </group>
        </group_list>
        <measure>
          <title>Device Procedural Time</title>
          <description>Evaluation of procedure time associated with use of the investigational device.</description>
          <units>minutes</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="85"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12" spread="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Contrast Use</title>
        <description>Evaluation of total procedural contrast volume use</description>
        <time_frame>Approximately 24 hours post procedure</time_frame>
        <population>Denominator is not to equal to 85 due to missing data on 4 patients.</population>
        <group_list>
          <group group_id="O1">
            <title>Wingman Crossing Catheter</title>
            <description>Use of the device to support CTO crossing&#xD;
Wingman Crossing Catheter: Endovascular CTO crossing</description>
          </group>
        </group_list>
        <measure>
          <title>Contrast Use</title>
          <description>Evaluation of total procedural contrast volume use</description>
          <population>Denominator is not to equal to 85 due to missing data on 4 patients.</population>
          <units>mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="81"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="148" spread="79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Fluoroscopic Time</title>
        <description>Evaluation of total procedural fluoroscopic time</description>
        <time_frame>Approximately 24 hours post procedure</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Wingman Crossing Catheter</title>
            <description>Use of the device to support CTO crossing&#xD;
Wingman Crossing Catheter: Endovascular CTO crossing</description>
          </group>
        </group_list>
        <measure>
          <title>Fluoroscopic Time</title>
          <description>Evaluation of total procedural fluoroscopic time</description>
          <units>minutes</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="85"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30" spread="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>30 days</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Wingman Crossing Catheter</title>
          <description>Use of the device to support CTO crossing&#xD;
Wingman Crossing Catheter: Endovascular CTO crossing</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="85"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute left ventricular failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Cardiac failure congestive</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Ventricular fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="85"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Procedural vomiting</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="85"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Vascular stent occlusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Vascular access site pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Vascular access site dissection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Arterial perforation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Vascular access site pseudoaneurysm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="85"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Contrast media reaction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="85"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Gangrene</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Abscess limb</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="85"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Vascular access site haematoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Vascular pseudoaneurysm</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Arterial bypass thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Vessel perforation</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Post procedural haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="85"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Respiratory failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="85"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="85"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Subclavian steal syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="85"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Acute kidney injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="85"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="85"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Peripheral arterial occlusive disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Arteriovenous fistula</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Peripheral embolism</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Peripheral artery thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Peripheral artery occlusion</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Intermittent claudication</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="85"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="85"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Vascular access site dissection</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Vascular access site haematoma</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="85"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Peripheral embolism</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="85"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Isa Rizk</name_or_title>
      <organization>Reflow Medical</organization>
      <phone>9494810399</phone>
      <email>info@reflowmedical.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

